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 ABSTRACT
Background: Evidence supporting deleterious effect of preformed major histocompatibility class I 
chain-related A (MICA) antibodies in rejection incidence and graft survival is still unclear. Methods: 
Retrospective analysis of 554 kidney transplanted patients. Comparison between positive or negative 
for MICA antibodies patients was performed to characterize sensitizing triggers. Further classification 
according to pre-transplant flow cytometry-recorded anti–MICA and/or anti-human leukocyte antigen 
(HLA) antibodies was made to determine first year rejection incidence and graft survival. Multivariate 
analysis was applied to determine predictors for acute rejection. Results: Pre-formed anti-MICA antibod-
ies were detected in 41 patients (7.4%). HLA sensitization, blood transfusions and pregnancies were 
frequently found in anti-MICA+ patients but only pre-formed anti-HLA class I antibodies showed inde-
pendent association (OR 2.67, p = 0.02). Comparing to MICA-/HLA–, MICA-/HLA+ group presented sig-
nificantly lower first year rejection-free survival (78.6% vs. 89.3%, p < 0.01), mostly occurred in the first 
six months, while no difference was found in MICA+/HLA– (88.9% vs. 89.3%, p = ns). MICA-/HLA+ showed 
independent impact in rejection (OR 2.09, p = 0.03), while no evidence was found in MICA+/HLA- (OR 
1.08, p = ns). At 4 years, MICA-/HLA+ group presented lower graft survival (85.8% vs. 95.3%, p = 0.03). 
Again, no difference was found in MICA+/HLA- group (95.1% vs. 95.3%, p = ns). Conclusion: Our results 
do not support HLA-independent deleterious pathogenic role of pre-formed MICA antibodies on first year 
rejection incidence and graft survival.
Key-Words: HLA; kidney; MICA; rejection; survival; transplant.
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 INTRODUCTION
In the past years, association between anti-human 
leukocyte antigen (HLA) sensitization and worse graft 
prognosis has been reinforced by several studies. 
The basis for these findings consists on antibody-
mediated rejection (AMR), which has been recognized 
as a major predictor of acute and chronic graft loss1. 
However, even in full matches at the HLA loci, graft 
rejection can still occur2, leading to an increasing 
belief that non-HLA antigens could be additional 
injury targets in transplant organs.
Major-histocompatibility-complex class (MHC) 
I-related chain A (MICA) has drawn major attention 
as a potential antigen target. The MICA gene is situ-
ated within the MHC region on chromosome 6p21.3 
centromeric to HLA-B in the class I region and 
encodes polymorphic surface glycoproteins with func-
tions related to innate immunity2. It has predominant 
expression on fibroblasts, epithelial, dendritic and 
endothelial cells, but can be upregulated and rec-
ognized by natural killer (NK) cells in virtually all 
tissues, including activated CD4+ and CD8+ cells, as 
a consequence of cell stress caused by cytomegalo-
virus (CMV) or other viral infections, tumours, auto-
immune disorders or ischemia-reperfusion injury3.
Since evidence of anti-MICA antibodies capability 
in complement activation and endothelial injury was 
found, further investigations were directed to identify 
the anti-MICA sensitization mechanisms in waiting list 
patients and to discover its role in antibody-mediated 
rejection mechanism and effect in graft survival3-6. 
Due to its polymorphic nature and endothelial pre-
sentation, exposure to allogenic MICA occurring in 
blood transfusion, pregnancies and during transplanta-
tion could elicit antibody formation, like allogenic HLA 
antigens. It has been suggested that pregnancy and 
retransplantion can induce MICA antibodies4-6 but the 
role of blood transfusions is still unclear since only 
one study showed this association6.
Several small reports suggested that preformed 
anti-MICA antibodies could have a role in antibody-
mediated rejection (AMR), since association to 
 RESUMO
Introdução: O efeito deletério dos anticorpos para antigénios MICA (major histocompatibility class I chain-
related A) na incidência de rejeição aguda e sobrevida do enxerto ainda não está consensualmente esta-
belecido. Metódos: Estudo retrospetivo de 554 transplantados renais. A análise comparativa entre doentes 
positivos e negativos para anticorpos anti-MICA pré-formados foi realizada para avaliar eventos sensibili-
zadores. A incidência de rejeição aguda no primeiro ano pós transplante renal e a sobrevida do enxerto 
renal foram determinadas consoante o resultado da citometria de fluxo pré-transplante para anticorpos 
anti-MICA e/ou anti- HLA (anti-human leukocyte antigen). Aplicou-se um modelo de análise multivariada 
para identificação de preditores independentes para rejeição aguda. Resultados: Foram identificados 41 
doentes (7.4%) com anticorpos anti-MICA pré formados. A sensibilização para HLA, as transfusões sanguíneas 
e gestações prévias foram mais frequentes nos doentes MICA + mas apenas a presença de anticorpos anti-
HLA classe I apresentou uma associação independente (OR 2.67, p = 0.02). Comparativamente ao grupo 
MICA-/HLA–, o grupo MICA-/HLA+ apresentou menor sobrevida livre de rejeição ao 1º ano (78.6% vs. 89.3%, 
p < 0.01), maioritariamente ocorrida nos primeiros seis meses, enquanto que nenhuma diferença foi encon-
trada com o grupo MICA+/HLA– (88.9% vs. 89.3%, p = ns). Apenas o status MICA-/HLA+ teve impacto 
independente na incidência de rejeição (OR 2.09, p = 0.03), ao contrário do status MICA+/HLA- (OR 1.08, 
p = ns). O grupo MICA-/HLA+ apresentou menor sobrevida do enxerto censurada para a morte aos 4 anos 
(85.8% vs. 95.3%, p = 0.03), não se verificando diferenças no grupo MICA+/HLA- (95.1% vs. 95.3%, p = 
ns). Conclusão: Os nossos resultados não suportam um efeito deletério dos anticorpos pré-formados para 
MICA, independente da sensibilização HLA, na incidência de rejeição aguda no 1º ano pós transplante e na 
sobrevida do enxerto.
Palavras-Chave: HLA; MICA; rejeição; rim; sobrevida; transplante.
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rejection events were found7. Additionally, pre-
formed anti-MICA antibodies were found to have 
deleterious effect on graft survival in one multicentre 
study8. However, this effect was not found in more 
recent reports that did not show an independent 
pathogenic role of anti-MICA antibodies on graft 
survival6,9.
The purpose of this study relies on description of 
demographic, clinical and transplant features associ-
ated to MICA sensitizing events. Afterwards, we anal-
yse the possible impact, independent or associated 
to anti-HLA antibodies, of pre-formed MICA antibodies 
in rejection incidence and graft survival.
 MATERIAL AND METHODS
We retrospectively analysed 554 patients who 
received a kidney transplant between 2007 and 2013 
in our unit. In all patients, pre-transplantation serum 
samples were collected and analysed for anti-MICA 
and anti-HLA antibodies. Data regarding demograph-
ic, clinical, induction and maintenance immunosup-
pressive therapy, delayed graft function, allograft 
survival and rejection episodes were collected from 
each kidney transplant recipient. Graft loss was con-
sidered to calculate death censored graft survival. 
Allograft rejection was defined as biopsy proven 
rejection and classified according to the Banff Con-
ference Report as updated in 200710.
Complement-dependent cytotoxicity panel-reactive 
antibodies test (CDC PRA) was performed in all 
patients and considered positive if cell lyses remained 
present after dithiothreitol (DTT) treatment, identify-
ing only IgG anti-HLA isotypes positive cases. Pre-
transplantation screening of patients was performed 
for MICA and HLA antibodies using LABScreen Mixed 
assay (One Lambda, Inc. Canoga Park, CA, USA) and 
considered positive when the mean fluorescence 
intensity (MFI) of each bead was above the cutoff 
defined by the manufacturer. Microbeads were cov-
ered with the major HLA class I and Class II antigens 
and MICA antigens 01, 02, 04, 07, 09, 12, 17, 18, 19 
and 27. HLA antibody specificity was confirmed by 
performing single antigen bead using LABScreen 
Single Antigen assay. Donor-specific antibody (DSA) 
positive reaction was defined above empirically deter-
mined MFI cutoff of 1000. However, this 
determination began in mid 2009, so almost half of 
our anti-HLA positive patients did not have DSA 
determination (47.6%). In order to avoid reducing 
statistical power of our analysis by removing these 
patients with unknown DSA identification, we con-
sidered only flow cytometry for anti-HLA antibodies 
results.
The association between demographic, clinical, 
immunological features and presence of pre-trans-
plant MICA antibodies was compared using Pearsons 
chi-squared test or Fisher’s exact test for categorical 
data and student’s t-test for numerical data. Further 
binary logistic regression analysis was applied to 
determine independent effect on variables presenting 
p < 0.1 in univariate analysis. Survival analysis was 
performed using the Kaplan-Meier method and com-
pared among groups by log rank analysis (global 
and pairwise comparisons). Logistic regression analy-
sis was used to evaluate predictors for rejection 
during first year post-transplantation. Variables that 
reached p < 0.1 in univariate analysis were stepwise 
entered into multivariate model to access their inde-
pendent effect. A p-value of less than 0.05 was 
considered significant. The SPSS 18.0 was used for 
analysis (SPSS, Inc. Chicago, IL, USA).
 RESULTS
Pre-formed anti-MICA antibodies were detected in 
41 patients (7.4%). Demographic and clinical charac-
teristics stratified for MICA antibody are listed in Table 
I. After univariate analysis, blood transfusion and 
pregnancy were associated to MICA antibodies, while 
no difference was noted regarding retransplantation, 
recipient/donor CMV status and positive panel-reactive 
antibody. Induction and maintenance immunosuppres-
sion was similar between both groups, although 
slightly less patients anti-MICA + received tacrolimus 
as part of their immunosuppressive regimens (not 
statistically significant) and only two were submitted 
to living donor transplant. In our series, 14 of 41 MICA 
+ patients were also anti HLA+ (34.1%), as opposed 
to 95 MICA- patients (18.5%). This difference reached 
statistical significance (p = 0.017). However, this dif-
ference is mainly attributed to anti- HLA class I anti-
bodies (31.7% vs. 15.8%, p = 0.01) and no difference 
was found in anti-HLA Class II antibodies between 
both groups. Given these results, binary logistic 
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regression analysis including blood transfusion, preg-
nancies and class I or class II HLA antibodies, revealed 
that only anti HLA class I antibodies were associated 
to positive MICA (OR 2.77, 1.20 – 6.38). Tendency for 
lower MICA+ prevalence in living donor transplant was 
found (OR 0.25; 0.06 – 1.05).
A total of 86 patients (15.5%) experienced acute 
rejection during the first year post-transplant. In ten 
patients, histology data was not available. In the 
remaining, acute cellular rejection predominated 
(72.3%), mainly Banff 2 grade (Banff 1a/1b: 32.9%; 
Banff 2a/2b: 39.5%). Acute antibody-mediated rejec-
tion (AAMR) was responsible for the remaining cases 
(25%) and two patients presented evidence of chronic 
AMR (2.6%).
Regarding post-transplant outcomes, delayed graft 
function occurred equally in MICA positive or negative 
groups (17.7% and 24.4%, respectively). The same 
was true for acute rejection and histological charac-
terization (acute cell rejection (ACR) / AAMR) was 
roughly similar in both groups. No differences were 
found in graft or patient survival during 30.3 ± 19.3 
Table I
Epidemiological, clinical and transplant features of anti-MICA + and anti-MICA- patients
n = 554
MICA –
(n = 513, 92.6%)
MICA+
(n = 41, 7.4%)
Univariate 
p- value
Multivariate OR 
(95% CI)
Multivariate 
p- value
Year
– 2007
– 2008
– 2009
– 2010
– 2011
– 2012
– 2013
34 (6.7%)
78 (15.2%)
108 (21.1%)
87 (17.0%)
97 (18.9%)
94 (18.3%)
15 (2.8%)
1 (2.4%)
6 (14.6%)
8 (19.5%)
11 (26.8%)
8 (19.5%)
7 (17.2%)
0 (0.0%)
0.618
Retransplantation 60 (11.7%) 7 (17.1%) 0.312
Dialysis time (months) 45.6 (20.0-84.6) 50.5 (27.6-108.3) 0.310
Total HLA MM 3.9 ± 1.4 3.7 ± 1.3 0.484
Patient age (years) 44.0 ± 14.7 45.0 ± 16.1 0.658
Donor age (years) 45 ± 15.1 44.1 ± 15.2 0.726
Patient male gender 310 (60.4%) 25 (60.9%) 0.945
Donor male gender 315 (61.4%) 31 (75.6%) 0.2
HLA MM 4-6 312 (60.8%) 22 (53.7%) 0.185
Living donor 91 (17.7%) 2 (4.9%) 0.03 0.25 (0.06-1.05) 0.059
HCV positive 17 (3.3%) 3 (7.3%) 0.196
Patient CMV+ 440 (85.8%) 39 (95.1%) 0.208
Donor CMV+ 459 (89.5%) 38 (92.7%) 1.0
PRA > 0% 158 (30.8%) 10 (24.4%) 0.390
Previous blood transfusion 170 (33.1%) 20 (48.9%) 0.044 1.13 (0.82-1.55) 0.473
Previous pregnancies 195 (38.1%) 12 (75%) 0.038 1.27 (0.60-2.68) 0.528
ATG use 166 (32.4%) 12 (29.3%) 0.654
IL2 inhibitor use 295 (57.5%) 28 (68.3%) 0.201
Tacrolimus use 497 (96.9%) 38 (92.7%) 0.044 0.47 (0.11-1.23) 0.082
Preformed anti-HLA 95 (18.5%) 14 (34.1%) 0.017
 Anti-HLA class I 81 (15.9%) 13 (31.7%) 0.010 2.67 (1.16-6.14) 0.021
 Anti-HLA class II 55 (10.7%) 7 (17.1%) 0.222 0.69 (0.25-1.93) 0.477
Delayed graft function 90 (17.5%) 10 (24.4%) 0.273
Acute rejection 66 (12.9%) 6 (14.6%) 0.746
 – CMR 42 (8.2%) 5 (12.2%) 0.403
 – AMR 15 (2.9%) 1(2.4%) 0.878
Death censured graft loss 16 (3.1%) 1 (2.4%) 0.808
Death 12 (2.3%) 2 (4.9%) 0.319
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months of follow-up. In order to further investigate 
the independent impact of MICA antibodies, regard-
less of anti-HLA recipient status, patients were char-
acterized into four categories: MICA-/HLA- (n = 413); 
MICA+/HLA- (n = 27); MICA-/HLA+ (n = 95) and MICA+/
HLA+ (n = 14).
Rejection-free survival curves for each group dur-
ing first year post-transplantation are showed in Fig. 
1. At first glance, anti-MICA status seems to mimic 
anti-HLA status. Anti-HLA positive groups, with or 
without MICA antibodies, presented lower first year 
rejection-free survival (76.8% and 78.6%, respec-
tively) comparing to MICA-/HLA- (89.3%) but statisti-
cal significance was only obtained in HLA+/MICA- after 
stepwise analysis (p = 0.001). No differences were 
found in MICA+/HLA- when compared to MICA and 
HLA negative patients (88.9% vs. 89.3%, p = 0.948) 
and positive MICA status did not present addictive 
effect on anti-HLA positive group.
Further comparisons between these four groups 
and timing of first rejection (overall, 0-6 months or 
6-12 months) were made (Table II). In the total 12 
months period, rejection incidence was superior in 
MICA-/HLA+ versus MICA-/HLA- (23.2% vs. 10.6%, p 
< 0.01). Subsequent analysis for each period revealed 
that allograft rejection was higher in the first six 
months after transplantation in MICA-/HLA+ vs. MICA-/
HLA- patients (17.9% vs. 6.7%, p = 0.001). No dif-
ferences were found in the other groups comparisons. 
The same analysis for each type of rejection (cellular 
or antibody-mediated) showed similar results (data 
not shown).
In order to evaluate the independent role of anti-
MICA status in rejection occurrence, logistic regres-
sion analysis was applied considering anti-MICA and 
anti- HLA antibodies, positive PRA, donor and recipi-
ent gender, recipient age, HLA mismatch, previous 
blood transfusion or pregnancy (Table III). The pro-
duction of anti-HLA antibodies was significantly asso-
ciated with first-year rejection occurrence: MICA-/
Figure 1
First year rejection-free survival according to anti-HLA and anti-MICA status.
MICA/HLA
First year 
AR-free 
(%)
Global p Pairwise p
0. –/– 89.3
(0) vs. (1)
0.948
(0) vs. (2) 
0.001
(0) vs. (3)
0.216
1. +/– 88.9
0.006
(1) vs. (2)
0.176
(1) vs. (3)
0.385
2. –/+ 78.6
(2) vs. (3)
0.385
3. +/+
76.8
Pairwise comparison between MICA/HLA groups related to first-year rejection-free survival.
Table II
Allograft rejection incidence at 0-6 months, 6-12 months and overall 12 
months periods after transplantation in patients groups (paired comparisons)
Acute rejection
n (%)
0.
MICA-/HLA-
n = 414
1.
MICA+/HLA-
n = 27
2.
MICA-/HLA+
n = 95
3.
MICA+/HLA+
n = 14
0-6 months
n = 49
28 (6.7) 2 (7.4) 17 (17.9) 2 (14.3)
Pairwise p values
(0) vs. (1)
0.898
(0) vs. (2)
0.001
(0) vs. (3)
0.278
(1) vs. (2)
0.185
(1) vs. (3)
0.482
(2) vs. (3)
0.740
Acute rejection
n (%)
0.
MICA-/HLA-
n = 414
1.
MICA+/HLA-
n = 27
2.
MICA-/HLA+
n= 95
3.
MICA+/HLA+
n = 14
6-12 months
n = 23
16 (3.9) 1 (3.7) 5 (5.3) 1 (7.1)
Pairwise p values
(0) vs. (1)
0.966
(0) vs. (2)
0.537
(0) vs. (3)
0.537
(1) vs. (2)
0.741
(1) vs. (3)
0.628
(2) vs. (3)
0.733
Acute rejection
n (%)
0.
MICA-/HLA-
n = 414
1.
MICA+/HLA-
n = 27
2.
MICA-/HLA+
n= 95
3.
MICA+/HLA+
n = 14
0-12 months
n = 72
44 (10.6) 3 (11.1) 22 (23.2) 3 (21.4)
Pairwise p values
(0) vs. (1)
0.937
(0) vs. (2)
0.001
(0) vs. (3)
0.204
(1) vs. (2)
0.171
(1) vs. (3)
0.375
(2) vs. (3)
0.886
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HLA+ presented stronger association when compared 
with control group after multivariate analysis (OR 
2.09: 1.10-3.98). Single production of anti-MICA anti-
bodies had no effect in first year rejection incidence 
(OR 1.08: 0.31-3.76), neither did the concomitant 
presence of anti-MICA and anti-HLA antibodies pres-
ent a stronger association when compared to the 
presence of anti-HLA antibodies alone (OR 1.74; 
0.45-6.72).
Among patients categorized according to anti-HLA 
and anti-MICA antibodies and considering a total of 
4 years follow-up (Fig. 2), tendency for lower death-
censured graft survival was found in MICA+/HLA+ 
when compared to MICA-/HLA- patients (82.5% vs. 
95.3%, p = 0.075). The lack of significance is justi-
fied by the small number of cases analysed in this 
group (n = 14). Worse graft prognosis was detected 
in MICA-/HLA+ (85.8% vs. 95.3%, p = 0.026), while 
similar graft survivals were shown between MICA+/
HLA- and MICA-/HLA- groups (95.1% vs. 95.3%)
 DISCUSSION
In our patients submitted to kidney transplant, 
we detected preformed anti-MICA antibodies in 7.4% 
of cases. This value is similar to the same pre-
transplantation anti-MICA antibodies prevalence 
reported by Sánchez-Zapardiel et al9, while in other 
studies anti-MICA antibodies determination varied 
from 11% to 25%8-11. The variation in these deter-
minations may be explained by the heterogeneous 
populations analysed in each study regarding gender 
distribution, retransplanted patients proportions and 
methodological differences in MICA antibodies deter-
mination. The number of different MICA specificities 
used for Anti-MICA antibodies in flow cytometry-
based reagents differs in all studies, varying from 
five to twenty three in recent ones6,8,9. Logically, 
higher number of known specificities will increase 
anti-MICA prevalence. Additionally, cytometry-flow 
beads bound to single recombinant MICA antigens 
used for IgG anti-MICA determinations varied between 
LSA-MIC kit (Gen-Probe Transplant Diagnostics) or 
LABScreen MICA Single Antigen kit (One Lambda), 
which invariably accentuates methodological differ-
ences. Real estimate of true anti MICA antibodies 
prevalence before transplantation will be difficult 
Table III
Independent predictors for first year rejection incidence
Univariate
Multivariate
Selection if p univ < 
0.1
OR (95%CI) p OR (95%CI) p
MICA/HLA
–/–
+/–
–/+
+/+
Reference
1.05 (0.30-3.63)
2.53 (1.43-4.48)
2.29 (0.62- 8.54)
0.011
0.937
0.001
0.216
Reference
1.08 (0.31- 3.76)
2.09 (1.10- 3.98)
1.74 (0.45 -6.72)
0.159
0.906
0.025
0.423
Patient age 1.01 (0.99- 1.03) 0.200
PRA > 0% 1.56 (0.93- 2.60) 0.092 0.682
Patient male gender 0.57 (0.35 –0.94) 0.029 0.567
Donor male gender 1.03 (0.60- 1.76) 0.908
MM HLA 4-6 vs 0-3 1.36 (0.78- 2.34) 0.276
Pregnancy 1.98 (1.14- 3.46) 0.016 0.328
Blood transfusion 1.43 (0.86 -2.37) 0.167
 
Figure 2
Impact of combined anti-HLA and anti-MICA status on death censored graft 
survival at 4 years follow-up.
MICA/
HLA
4-years death 
censured graft 
survival (%)
Global p Pairwise p
0. –/– 95.3 0.074
(0) vs. (1)
0.997
(0) vs. (2)
0.026
(0) vs. (3)
0.075
1. +/– 95.1
(1) vs. (2) 
0.408
(1) vs. (3)
0.353
2. –/+ 85.8
(2) vs. (3)
0.594
3. +/+ 82.5
Pairwise comparison between MICA/HLA groups related to four years death censured 
graft survival.
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until uniformity and consensual methodology in MICA 
antibodies determination is achieved.
During the present study, we tried to determine 
the factors associated to anti MICA sensitization in 
patients submitted to kidney transplant, notwith-
standing our small number of MICA positive cases. 
In addition, we analysed if classic anti-HLA sensitizing 
events also induced anti-MICA sensitization. History 
of previous transplantation was not more frequent 
in the MICA+ group, similarly to previous reports8,9. 
No differences were found regarding recipient’s or 
donor’s gender. Previous reports found tendency for 
higher association between male recipient and MICA 
positivity despite the potential role of pregnancy as 
a sensitizing event6,8. In these studies, the reason 
for the influence of male gender on the presence of 
MICA antibodies was unclear and further investiga-
tion was required. Nevertheless, this association was 
not verified in other studies5,9.
Blood transfusions or pregnancy history occurred 
more frequently in MICA+ patients and concomitant 
higher detection of anti-HLA antibodies in these 
patients would make us consider that those events 
are causative for both antibodies formation. However, 
this hypothesis dissipates when only anti-HLA forma-
tion showed independent role on MICA sensitization. 
Lemy et al.6 identified previous transfusion and 
pregnancy as independent risk factors for develop-
ment of MICA antibodies. The absence of this effect 
in our sample may be related to our lesser number 
of patients submitted to blood transfusions when 
compared to Lemy’s study (34.3% vs. 48.1%) and 
in different pregnancy variable categorization (we 
included any episode as positive, while Lemy con-
sidered positive more than two episodes).
Patients sensitized against MICA antigens were 
more likely to have antibodies against HLA as well. 
Interestingly, only HLA class I sensitization showed 
independent association with MICA antibodies forma-
tion, suggesting that similar sensitizing events can 
produce anti-MICA and anti-HLA antibodies simulta-
neously. Endothelial cell injury caused by inflamma-
tion, ischaemia or viral infections induces higher 
expression of both HLA Class I and MICA antigens 
in cells. One example is CMV infection, which has 
been showed to upregulate the expression of MICA 
antigens forms and causes a possible anti-MICA anti-
body response12,13. We analysed whether anti-CMV 
positivity was more frequent in MICA+ patients, but 
no difference was found, like previously reported9.
In our unit, living donor transplant is mostly per-
formed in pre-emptive manner, although some 
patients may start dialysis while waiting for conclusive 
donor evaluation. Interestingly, living donor patients 
tended to present less frequently anti MICA antibod-
ies (OR 0.25, p = 0.059). In one previous study, 
chronic kidney disease (CKD) stage 5 was found to 
present increased prevalence of MICA immunization 
when compared to controls, regardless of transfu-
sions and transplantation events6. One possible 
explanation for these results is uraemia induced 
endothelial cells stress with increased MICA antigen 
or cumulative exposure to dialysis filters and dialysate 
fluids. Lower cumulative time on CKD stage 5 and 
under dialysis treatment may explain our lower MICA 
sensitization on living donor transplanted patients.
Evidence pointing to a direct pathogenicity of 
MICA antibodies in rejection events is essentially 
circumstantial, mainly based on higher frequency of 
MICA antibodies detection among patients that expe-
rienced rejection4. However, concomitant anti-HLA 
antibodies presence in these cases makes difficult 
to infer a causative role of anti-MICA antibodies. In 
our study, allograft rejection was observed more 
frequently only in MICA-/HLA+ and most episodes 
occurred in the early six months period (Table II), a 
typical feature of rejection mediated by pre-formed 
antibodies. Furthermore, preformed MICA antibodies 
showed no independent role in allograft rejection 
occurrence, regardless of anti HLA antibodies detec-
tion. Stepwise analysis has not shown lower rejec-
tion-free survival of MICA positive patients without 
HLA sensitization when compared to the control 
group. In fact, only three patients experienced rejec-
tion in the MICA+/HLA- group. The small number of 
events may have underpowered any potential caus-
ative role of anti MICA antibodies. Nevertheless, 
previous studies were also not able to show increased 
risk for rejection in MICA+ patients reporting similar 
first year cumulative rejection episodes comparing 
to MICA- patients6. Only one study showed borderline 
association between MICA+/HLA– patients and rejec-
tion incidence during the first 3 months when com-
pared to the control group (8% vs. 2%, p = 0.049)9.
One immunohistochemistry study14 has showed 
increased MICA antigen expression in podocytes 
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within the glomeruli during rejection events, as well 
within infiltrating mononuclear cell, B cells, CD8+ T 
cells and NK cells. Logically, AMR mechanisms could 
be present especially because MICA antibodies are 
capable of complement-dependent cell injury. Addi-
tionally, direct CD8+ T and NK cells activation via 
NKG2D ligands engaging MICA antigen could make 
possible to increase direct cellular-mediated lyses 
mechanisms during the rejection episode14. Previous 
reports failed to show an independent association 
of MICA antibodies in antibody-mediated rejection 
episodes, while higher frequency of cellular mediated 
rejection (CMR) in MICA+ patients has been described5. 
This finding was not achieved in our study since 
similar proportion of CMR episodes between overall 
MICA+ and MICA- patients and after MICA/HLA char-
acterization was found. Lack of independent patho-
logic role of anti MICA antibodies in AMR events 
may be related to the already know stronger effect 
of anti-HLA antibodies also found in these patients, 
masking any potential independent pathogenicity of 
MICA sensitization.
The present data argues against a significant effect 
of preformed MICA antibodies on graft survival. Pos-
sible addictive deleterious effect of MICA sensitization 
on already HLA sensitized patients is suggested after 
graft survival curves analysis but statistical signifi-
cance was not achieved, probably due to the small 
number of cases. In two major studies that evaluated 
the effect of pre-transplant MICA sensitization on 
graft survival, considering overall and only negative 
PRA cases, showed broadly dissimilar results. The 
first one, a multicentre cohort of 1910 kidney trans-
plant recipients8 showed not only association 
between preformed anti MICA antibodies and lower 
graft survival but also a stronger deleterious effect 
on first graft transplants, lower HLA mismatches and 
in absence of panel-reactive HLA antibodies, sug-
gesting an independent role of MICA antibodies. 
However, another cohort study6 with 10 years follow-
up showed similar first year rejection incidence and 
overall graft survival in MICA patients, comparing to 
MICA negative group. Further analysis considering 
only primary grafts revealed the same outcome. The 
conflicting results between these studies were 
explained by differences in immunosuppressive pro-
tocols, since lower induction therapy and lower 
prevalence in tacrolimus and MMF use were found 
in the one that showed lower first year graft survival. 
Therefore, the impact of MICA antibodies could be 
attenuated under heavier immunosuppression. In our 
case, about 90% of patients performed induction 
therapy, with antithymocyte globulin (32.1%) or IL-2 
receptor inhibitor (58.3%), and practically all used 
tacrolimus (95.5%) in maintenance therapy. More 
recently, the Sanchez-Zapardiel group9 also failed to 
show lower graft survival in MICA+/HLA- patients and 
justified their results because of the small sample 
size (n = 25) and higher efficiency of modern drugs, 
allowing better resolution of rejection episodes.
In order to achieve true impact of MICA antibodies 
on kidney transplantation it is necessary to deter-
mine the pathogenic role of MICA donor-specific 
antibodies (MICA DSA) instead of just taking into 
account the presence or absence of antibodies 
regardless of donor specificity. Therefore, MICA 
alleles typing of patients and donors would allow 
MICA mismatching determination and identification 
of pre-formed MICA DSA. Cox et al5 have shown 
that mismatching MICA alleles could lead to post-
transplant MICA antibodies and these antibodies 
were independently associated with decreased glo-
merular filtration rate and poorer graft outcome in 
the first two years after transplantation. These find-
ings suggest that MICA DSA antibodies could have 
distinct pathologic role to HLA DSA antibodies, 
contributing to deleterious graft outcome.
In summary, our data did not show a meaningful 
pathogenic role of preformed MICA on first year 
rejection incidence or allograft survival in our centre. 
It further shows that the study of pre-transplant MICA 
sensitization and impact on kidney transplantation 
is severely hampered by the low prevalence of MICA 
detection and their frequent association with HLA 
antibodies. Therefore, further studies enclosing high-
er number of patients analysed, methodological uni-
formity in MICA antibodies identification and donor 
specificity determination will be needed to assess 
the possible independent role of preformed MICA in 
post-transplant outcomes.
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